Abstract
Most traditional treatments for type 2 diabetes fail to achieve and maintain effective glycaemic control,due to a progressive decline in β-cell function and a corresponding increase of blood glucose levels over time.The loss of β-cell function to 50% at diagnosis indicates that both diagnosis and.treatment initiation take place as early as possible in the progress of diabetes,before β-cell decline proceeds too far.This review describes the role of β-eell in both normal metabolism and type 2 diabetes,summarizes the current treatments for type 2 diabetes,and explores the prospect of incretin-based(especially GLP-1 analogues) therapies.GLP-1 analogues may offer more than glycaemic control alone:they may also facilitate weight loss and improve the natural history of diabetes by β-cell protection. Key words: β cells; GLP-1; GLP-1 analogues; lncretin; Type 2 diabetes mellitus
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
